AzTrials
AzTrials

Genetic and Inflammatory PolyneuropathiesPOLYFRANCT07851844

Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France

An observational study of Genetic and Inflammatory Polyneuropathies, run by Assistance Publique - Hôpitaux de Paris at 26 sites in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

To describe the clinical, electrophysiological, and genetic characteristics of patients with genetic and inflammatory polyneuropathies in France. Read more about this study

Who is it for?
Ages 18 years and older
How many people
1,000 participants
Where
26 sitesFrance
Study dates
1 Nov 2026to 1 Nov 2036
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults diagnosed with genetic or inflammatory polyneuropathy and followed in participating neurology centers in France.

Who may be able to join

  • Adult patients aged 18 years or older.
  • Patients with a diagnosis of genetic or inflammatory polyneuropathy, confirmed by complementary examinations performed as part of routine care, including genetic, biological and/or electrophysiological tests.

Who cannot join

  • Patient opposition to the use of their routine care data for research purposes.

Trial locations and contacts

26 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Andoni ECHANIZ-LAGUNA contact

+33(0)145212677

andoni.echaniz-laguna@aphp.fr

26 sites in 1 country

France26 sites

  • CHU Amiens-Picardie - Site Sud

    Amiens

    Philippe-Edouard MERLE, merle.philippe@chu-amiens.fr

  • CHU Angers

    Angers

    Julien CASSEREAU, JuCassereau@chu-angers.fr

  • Hôpital Pellegrin, CHU Bordeaux

    Bordeaux

    Guilhem SOLE

  • Hôpital Morvan, CHU Brest

    Brest

    Steeve GENESTET, steeve.genestet@chu-brest.fr

  • Hôpital Pierre Wertheimer, HCL

    Bron

    Juliette SVAHN, juliette.svahn@chu-lyon.fr

  • Hôpital Gabriel-Montpied, CHU Clermont-Ferrand

    Clermont-Ferrand

    Frédéric TAITHE, ftaithe@chu-clermontferrand.fr

  • Hôpital François Mitterrand, CHU Dijon

    Dijon

    Agnès JACQUIN-PIQUES, agnes.jacquin-piques@chu-dijon.fr

  • Centre Hospitalier Annecy Genevois

    Épagny

    Océane BOUCHOT, obouchot@ch-annecygenevois.fr

  • Hôpital Raymond-Poincaré

    Garches

    Edouard BERLING, edouard.berling@aphp.fr

  • CHU Grenoble - Site Sud

    Grenoble

    Emmeline LAGRANGE, ELagrange@chu-grenoble.fr

  • CHU de la Réunion - GH Sud Réunion - Saint-Pierre

    La Réunion

    Ariane CHOUMERT, ariane.choumert@chu-reunion.fr

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre

    Andoni ECHANI-LAGUNA, andoni.echaniz-laguna@aphp.fr

  • Hôpital Salengro, CHU de Lille

    Lille

    Céline TARD, celine.tard@chu-lille.fr

  • Hôpital Dupuytren, CHU Limoges

    Limoges

    Laurent MAGY, laurent.magy@chu-limoges.fr

  • Hôpital de la Timone, AP-HM

    Marseille

    Shahram ATTARIAN, shahram.attarian@ap-hm.fr

  • F-Esselin@Chu-Montpellier.Fr

    Montpellier

    Florence ESSELIN, f-esselin@chu-montpellier.fr

  • CHU Nantes - Hôtel-Dieu - Hôpital Mère-Enfant

    Nantes

    Yann PEREON, Yann.Pereon@univ-nantes.fr

  • Hôpital Pasteur, CHU Nice

    Nice

    Sabrina SACCONI, SACCONI.S@chu-nice.fr

  • Hôpital Universitaire Carémeau, CHU Nîmes

    Nîmes

    Ioana Maria ION

  • Hôpital Ambroise Paré

    Paris

    Pierre LOZERON, pierre.lozeron@aphp.fr

  • Hôpital La Pitié-Salpetrière

    Paris

    Tanya STOJKOVIC, tanya.stojkovic@aphp.fr

  • Hôpital Maison Blanche, CHU Reims

    Reims

    Maxime KIRCHHOFER, mkirchhofer@chu-reims.fr

  • Hôpital Charles-Nicolle, CHU Rouen

    Rouen

    Anne-Laure BEDAT-MILLET, anne-laure.millet@chu-rouen.fr

  • Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg

    Strasbourg

    Jean-Baptiste CHANSON, jean-baptiste.chanson@chru-strasbourg.fr

  • Hôpital Rangueil, CHU Toulouse

    Toulouse

    Pascal CINTAS, cintas.p@chu-toulouse.fr

  • Hôpital Bretonneau CHRU de Tours

    Tours

    Stéphane BELTRAN, s.beltran@chu-tours.fr

Other trials in France

About this study

To describe the clinical, electrophysiological, and genetic characteristics of patients with genetic and inflammatory polyneuropathies in France.

Read the detailed description

To describe the clinical, electrophysiological, and genetic characteristics of genetic and inflammatory peripheral neuropathies in detail in order to advance our understanding of these rare and disabling diseases. This detailed description is also necessary with a view to the future use of innovative treatments. In recent years, there have indeed been spectacular advances in the field of genetic therapies (siRNA, antisense oligonucleotides, gene therapy) and next-generation immunosuppressive therapies (complement inhibitors, anti-FcRN), all of which are applicable in the short- to medium-term for genetic and inflammatory polyneuropathies.

This is a multicenter, prospective-retrospective study using data collected as part of routine clinical care.The objectives are as follows:

  • Describe the different subtypes of genetic and inflammatory pyneuropathies in France
  • Describe the demographic characteristics
  • Describe the geographic distribution
  • Describe the electrophysiological findings
  • Describe the genetic abnormalities
Keywords
Rare Diseases, Genetic Testing, Electrophysiology, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Charcot-Marie-Tooth Disease, Inflammatory Neuropathy, Hereditary Neuropathy, Polyneuropathy
Medical subject headings
Neuritis, Rare Diseases, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Charcot-Marie-Tooth Disease, Polyneuropathies

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number and percentage of participants by type of polyneuropathy

    Participants will be classified as having genetic or inflammatory polyneuropathy according to the diagnosis documented in their medical records. The number and percentage of participants in each category will be reported.

    Measured: At inclusion, based on the diagnosis documented in the medical record.

Secondary outcomes (5)

  1. Number and percentage of participants by polyneuropathy subtype

    The number and percentage of participants in each genetic or inflammatory polyneuropathy subtype, as documented in the medical records, will be reported.

    Measured: At inclusion, based on the diagnosis documented in the medical record.

  2. Demographic characteristics of patients

    Description of demographic characteristics of patients with genetic or inflammatory polyneuropathies, including age, sex and other available demographic data.

    Measured: At baseline, corresponding to the date of inclusion in the study, using data available in the medical record up to that date.

  3. Geographical distribution of patients

    Description of the geographical distribution of patients with genetic or inflammatory polyneuropathies included in participating centers in France.

    Measured: At baseline, corresponding to the date of inclusion in the study, using data available in the medical record up to that date.

  4. Number and percentage of participants by electrophysiological neuropathy pattern

    The electrophysiological neuropathy pattern documented in the medical record will be classified as axonal, demyelinating or mixed. The number and percentage of participants in each category will be reported.

    Measured: At inclusion, based on electrophysiological examinations available in the medical record.

  5. Genetic abnormalities

    Description of genetic abnormalities identified in patients with genetic or inflammatory polyneuropathies, when genetic analysis results are available in the medical records.

    Measured: At baseline, corresponding to the date of inclusion in the study, using genetic data available in the medical record up to that date.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Oct 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion1 Nov 2036 (estimated)
  4. Study completion1 Nov 2036 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07851844
Sponsor's protocol ID
APHP260582
Acronym
POLYFRA
Status last verified
Jun 2026
First submitted
22 Jun 2026
Last updated
1 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Genetic and Inflammatory Polyneuropathies, run by Assistance Publique - Hôpitaux de Paris at 26 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 26 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Andoni ECHANIZ-LAGUNA (+33(0)145212677, andoni.echaniz-laguna@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number and percentage of participants by type of polyneuropathy (time frame: At inclusion, based on the diagnosis documented in the medical record.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07851844.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in